Pathkind Diagnostics and Hero Electrics entered into a partnership, wherein Hero Electric scooters will be customised for Pathkind with cargo attachments to store critical equipment for all health-metric tests.
New Delhi, Jul 10 (PTI) Hero Electric on Friday announced a partnership with Pathkind Diagnostics to provide its customised electric scooters to the latter for sample collections across India.
Hero Electric, a pioneer in the electric vehicle industry in India, today announced its Be Safe – Keep Safe program in collaboration with Pathkind Diagnostics – a leader in healthcare and diagnostics.
Home to Home Hero Electric bikes ensure complete safety of riders as well as patients
Hero Electric on Friday announced a partnership with Pathkind Diagnostics to provide its customised electric scooters to the latter for sample collections across India.
Hero Electric, a pioneer in the electric vehicle industry in India, today announced its Be Safe – Keep Safe program in collaboration with Pathkind Diagnostics – a leader in healthcare and diagnostics. During this COVID-19 crisis, being safe while keeping others safe is very critical.
In a recent announcement, Pathkind Labs (diagnostics arm of Mankind Pharma) appointed Auburn Digital Solutions as the digital marketing agency.
The account was won following a multi agency pitch and will be handled out of the agency’s Delhi office. This win adds to the growing kitty of Auburn’s clients in India.
In a recent interview with Health Biz Insight, Mr. Sanjeev Vashishta, MD & CEO of PathKind Diagnostics threw some light on PathKind’s unique strategy of targeting North India’s tier 2, 3 & 4 locations before moving to the bigger cities.
He stated that PathKind intends to invest a little over Rs. 400 crore in the diagnostics business, and is aiming to bring standardization across all their centers in terms of systems, processes, and operating protocols. Providing the people of India access to meaningful technologies and tests, which are specific, sensitive, and affordable at the same time, were some of the key highlights of his conversation.
When asked about the future business plans in the end, Mr. Vashishta said that PathKind is looking to have a pan-India presence in the next 5 years, and planning to turn their EBIDTA positive in the 5th year.
Mankind Pharma mulls to invest Rs 305-crore in Pathkind Diagnostics
Mankind Pharma, a USD 800 million pharmaceutical company, is foraying into Diagnostics space with its new venture Pathkind Diagnostics. In the coming 4 years, the company has a plan to invest Rs 305 crore in its new venture, which will start its operation from August 2017.
As a part of the strategy, Pathkind would aim to reach out to the masses in tier 2/3 cities in India with the direct and clear-cut approach of providing easily accessible high quality diagnostics services at affordable prices.
Mankind Pharma’s decision of launching the new Diagnostics chain, Pathkind, is to focus on organic growth. The company is planning to open 12 large labs, 20 rapid response labs and 150 collection centres in 12 months and will operate on a three-tier model. With a reference lab in Gurgaon, it will also have multiple collection centers in small towns and villages, which will be connected through the network of labs.
Initially, the company will start its operations from Uttar Pradesh and move to Uttarakhand. To promote this new venture in the Diagnostics space, Mankind has joined hands with Sanjeev Vashishta.
Sanjeev Vashishta has been known for his ability of connecting with people and for his potential to turn around businesses. Prior to joining Pathkind Labs, he successfully managed running operations (a cluster of hospitals) in the Fortis group with whom he was around for 11 years. He was also responsible for the dramatic transformation of SRL’s business in just 4 years.
Sanjeev Vashishta, Managing Director of Pathkind, said,” Diagnostics industry in India is grossly under-penetrated. Given the fact that diagnosis costs fraction in comparison to the cost of treatment, and about 20 percent of the Indian population has ever got a blood test done due to inaccessibility/ignorance, the volumes could be taken up significantly by just educating the prescribers (about new modalities) and the masses.
“There is a huge dearth of quality service providers in India, as per the demand for the healthcare/ diagnostics services. Venturing into diagnostics is also a financially prudent decision as diagnostics model is asset light, with low gestation period and a lucrative RoI,” he added.
“At Pathkind, we are strongly committed to serve at the grass root level so that the masses don’t have to travel miles in order to get themselves diagnosed. Our aim is in line with the government’s vision to provide quality diagnostics/ healthcare access at an affordable price,” Vashishta said.
“It will be our endeavour to provide accurate diagnostics in the shortest possible time. Furthermore, as per the National Health Policy 2017 the govt of India is committed to give the much needed importance to Universal Health and the Government intends to increase the healthcare spend from a meagre 1 percent to 2.5 percent of GDP in the near future.”
Mankind Pharma, a US$ 800 million pharmaceutical company, is foraying into diagnostics space with its new venture Pathkind Diagnostics. In the coming 4 years, the company has a plan to invest Rs. 305 crore in its new venture, which will start its operation from August 2017. As a part of the strategy, Pathkind would aim to reach out to the masses in tier 2/3 cities in India with the direct and clear-cut approach of providing easily accessible high quality diagnostics services at affordable prices.
Mankind Pharma’s decision of launching the new diagnostics chain, Pathkind, is to focus on organic growth, contrasting with the game plans of its competitors. The company is planning to open 12 large labs, 20 rapid response labs and 150 collection centres in 12 months and will operate on a three-tier model. With a reference lab in Gurgaon, it will also have multiple collection centers in small towns and villages, which will be connected through the network of labs. Initially, the company will start its operations from Uttar Pradesh and move to Uttarakhand. To promote this new venture in the diagnostics space, Mankind has joined hands with Sanjeev Vashishta.
Sanjeev Vashishta has been known for his ability of connecting with people and for his potential to turn around businesses. Prior to joining Pathkind Labs, he successfully managed running operations (a cluster of hospitals) in the Fortis group with whom he was around for 11 years. He was also responsible for the dramatic transformation of SRL’s business in just 4 years.
Commenting on the same, Sanjeev Vashishta, managing director & CEO of Pathkind, said,” Diagnostics industry in India is grossly under-penetrated. Given the fact that diagnosis costs fraction in comparison to the cost of treatment, and about 20% of the Indian population has ever got a blood test done due to inaccessibility/ignorance, the volumes could be taken up significantly by just educating the prescribers (about new modalities) and the masses. There is a huge dearth of quality service providers in India, as per the demand for the healthcare/ diagnostics services. Today, people are becoming conscious about their health, which results in the need of more quality diagnostics centres. Venturing into diagnostics is also a financially prudent decision as diagnostics model is asset light, with low gestation period and a lucrative ROI. “
He further added; “At Pathkind, we are strongly committed to serve at the grass root level so that the masses don’t have to travel miles in order to get themselves diagnosed. Our aim is in line with the government’s vision to provide quality diagnostics/ healthcare access at an affordable price. It will be our endeavour to provide accurate diagnostics in the shortest possible time. Furthermore, as per the National Health Policy 2017 the govt of India is committed to give the much needed importance to Universal Health and the Govt. intends to increase the healthcare spend from a meagre 1% to 2.5% of GDP in the near future”.
In recent times, several companies have evinced interest in getting into the diagnostics arena. Mankind has a strong presence in pharmaceutical, veterinary, OTC & FMCG segments with over 63 brands ranked at No. 1 position in their respective segments. Besides having a strong presence in the domestic market, Mankind is present across various countries in Asia & Africa. The company has ventured into a new business of diagnostics with an aim to emerge as a leading domestic player.
Mankind Pharma set to foray into diagnostics with Pathkind
